May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
Ocular Effects of Nepafenac Ophthalmic Suspension in New Zealand White Rabbits Undergoing Partial Corneal Incisions
Author Affiliations & Notes
  • D.H. McGee
    Toxicology, Alcon Research, Ltd., Fort Worth, TX
  • J.D. Heaton
    Toxicology, Alcon Research, Ltd., Fort Worth, TX
  • M.M. Gruebbel
    Experimental Pathology Laboratories, Inc., Durham, NC
  • R.B. Hackett
    Toxicology, Alcon Research, Ltd., Fort Worth, TX
  • R.L. Rice
    Toxicology, Alcon Research, Ltd., Fort Worth, TX
  • J.W. Hiddemen
    Toxicology, Alcon Research, Ltd., Fort Worth, TX
  • Footnotes
    Commercial Relationships  D.H. McGee, Alcon Research, Ltd. E; J.D. Heaton, Alcon Research, Ltd. E; M.M. Gruebbel, Alcon Research, Ltd. C, R; R.B. Hackett, Alcon Research, Ltd. E; R.L. Rice, Alcon Research, Ltd. E; J.W. Hiddemen, Alcon Research, Ltd. E.
  • Footnotes
    Support  Alcon Research,Ltd.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 2648. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      D.H. McGee, J.D. Heaton, M.M. Gruebbel, R.B. Hackett, R.L. Rice, J.W. Hiddemen; Ocular Effects of Nepafenac Ophthalmic Suspension in New Zealand White Rabbits Undergoing Partial Corneal Incisions . Invest. Ophthalmol. Vis. Sci. 2005;46(13):2648.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To determine the ocular effects of Nepafenac Ophthalmic Suspension dosed prior to and for one month following partial corneal incision in New Zealand white rabbits. Methods: Four groups of 8 rabbits each were randomly assigned to receive either 0%, 0.1%, 0.3%, or 1.0% Nepafenac Ophthalmic Suspension (preserved with 0.01% BAK). Treatment with 2 drops (total 80 microliters) 4 times a day in the right eye began 7 days before the partial thickness corneal incision and continued for 34 days. The left eye served as an untreated control. After 7 days of dosing, a 3 to 5 mm incision to a depth of 60% of the corneal thickness was made parallel to the limbus. A fifth group of 8 rabbits (sham control group) received a corneal incision, but no topical treatment. Slit–lamp examination was performed at baseline and on Days 5, 9, 14, 20, 29, and 34. Indirect ophthalmoscopy was conducted at baseline and after approximately 1 month of treatment. Pachymetry was performed at baseline and on Days 7, 15, and 28. On Day 35, ocular tissues and adnexa were obtained for histological examination. Results: Biomicroscopy revealed mild to moderate conjunctival hyperemia and transient, sporadic minimal conjunctival discharge with Nepafenac and Vehicle following the incision period. In every case, the discharge resolved by the next examination. Fluorescein staining showed complete reepithelialization following incision with no differences among groups. Indirect ophthalmoscopy revealed no fundus abnormalities in any group. No statistical differences in central corneal thickness occurred between Nepafenac–treated, vehicle–treated, and untreated control eyes. At necropsy, no gross abnormalities were observed in the ocular tissues. Microscopic evaluation of ocular tissues revealed minimal to mild corneal epithelial hyperplasia at the incision site consistent with regeneration after corneal incision in all operated eyes of the Nepafenac, Vehicle, and sham groups. Conclusions: Four–times–daily topical ocular dosing with Nepafenac Ophthalmic Suspension, 0.1%, 0.3%, or 1.0% did not induce ocular irritation or toxicity, or delay corneal wound healing when administered for 7 days prior to and continued for 27 days following a partial thickness corneal incision.

Keywords: cornea: basic science • inflammation 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×